ACR-ACNM-ARS-SNMMI 镭-223二氯化物治疗实践参数
该实践参数由美国放射学会(ACR)、美国核医学学会(ACNM)、美国镭学会(ARS)和核医学与分子影像学会(SNMMI)联合修订,是对2019年版镭-223治疗实践参数的更新。修订基于2019年初始文件发布以来收集和综述的文献报告,内容涵盖该药剂的物理性质、当前及研究性适应证、人员资质与职责、评估检查与治疗规范、非密封放射性药物源的治疗使用、辐射安全及质量控制。该文件旨在指导经过适当培训和认证的医师实施镭-223二氯化物治疗。
要点
- 该实践参数为2019年版镭-223治疗参数的更新,由ACR、ACNM、ARS和SNMMI联合修订。
- 更新纳入2019年以来关于镭-223在多种转移性癌症部位及转移性激素抵抗性前列腺癌中应用的研究报告。
- 内容涵盖物理性质、适应证、人员资质、评估与治疗规范、辐射安全及质量控制。
核心结论
- 该更新版实践参数旨在指导经过适当培训和认证的医师实施镭-223二氯化物治疗,综合考虑患者与放射性同位素管理的各个方面、当前适应证及正在进行的研究。
研究设计与样本
- 该实践参数由ACR核医学与分子影像委员会实践参数-核医学与分子影像委员会及ACR放射肿瘤学委员会实践参数-放射肿瘤学委员会,与ACNM、ARS和SNMMI合作,按照ACR网站所述「制定ACR实践参数和技术标准的过程」进行修订;收集并综述了自2019年初始文件发布以来可获得的报告。
临床应用与阅片要点
- 该实践参数涉及镭-223的物理性质、当前及研究性适应证、人员资质与职责、评估检查与治疗规范、非密封放射性药物源的治疗使用、辐射安全及质量控制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The document represents an update of the radium-223 therapy practice parameter developed by the societies in 2019.
METHODS: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website ( https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards ) by the Committee on Practice Parameters-Nuclear Medicine and Molecular Imaging of the ACR Commissions on Nuclear Medicine and Molecular Imaging and the Committee on Practice Parameters-Radiation Oncology of the ACR Commission on Radiation Oncology, in collaboration with the ACNM, the ARS, and the SNMMI. Reports available since the publication of the initial document in 2019 were collected and reviewed.
RESULTS: Since the publication of the initial radium-223 practice parameter in 2019, there has been significant investigation of the agent in the management of numerous metastatic cancer sites, in addition to additional studies of its use in metastatic hormone-resistant prostate cancer. This updated document considers physical properties of the agent, current and investigative indications, qualifications and responsibilities of personnel, specifications of the evaluation exam and treatment, the therapeutic use of unsealed radiopharmaceutical sources, radiation safety, and quality control.
CONCLUSIONS: This updated practice parameter is intended to guide appropriately trained and credentialed physicians performing therapy with radium-223 dichloride. All aspects of patient and radioisotope management are considered, as are current indications and ongoing investigations.
引用
- Akin EA, Wallner PE, Alexander S, et al. ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride. Am J Clin Oncol. 2025. PMID: 40851434. doi:10.1097/COC.0000000000001245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。